相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer
Georgina E. Wood et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
Maha Elazezy et al.
MOLECULAR ONCOLOGY (2021)
Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook
Evi Lianidou
MOLECULAR ONCOLOGY (2021)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Cystatin M/E (Cystatin 6): A Janus-Faced Cysteine Protease Inhibitor with Both Tumor-Suppressing and Tumor-Promoting Functions
Gilles Lalmanach et al.
CANCERS (2021)
USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer
Dora Londra et al.
CANCERS (2021)
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
Claudia Winkler et al.
JCI INSIGHT (2021)
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lloreta Kerliu et al.
ANNALS OF PHARMACOTHERAPY (2020)
Newly diagnosed ovarian cancer: Which first-line treatment?
Domenica Lorusso et al.
CANCER TREATMENT REVIEWS (2020)
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
Roshni D. Kalachand et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Recent advances in circulating nucleic acids in oncology
A. Otandault et al.
ANNALS OF ONCOLOGY (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives
Alka Singh et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
Kevin Shee et al.
PLOS ONE (2019)
USP44 is dispensable for normal hematopoietic stem cell function, lymphocyte development, and B-cell-mediated immune response in a mouse model
Yun Hsiao Lin et al.
EXPERIMENTAL HEMATOLOGY (2019)
Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?
Julie L. Hentze et al.
MOLECULAR AND CLINICAL ONCOLOGY (2019)
Association of MGMT promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis
Baoli Qiao et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2018)
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Gwynn Ison et al.
CLINICAL CANCER RESEARCH (2018)
ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer
Lydia Giannopoulou et al.
GYNECOLOGIC ONCOLOGY (2018)
Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers
Lorena Losi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
ILaria Colombo et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
Xinxin Zhu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Principles of DNA methylation and their implications for biology and medicine
Yuval Dor et al.
LANCET (2018)
Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters
Nisreen Al-Moghrabi et al.
CLINICAL EPIGENETICS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Application of Cell-free DNA Analysis to Cancer Treatment
Ryan B. Corcoran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer
Han-Wei Lin et al.
EPIGENOMICS (2018)
ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
Sophia Mastoraki et al.
CLINICAL CANCER RESEARCH (2018)
Potential clinical applications of circulating cell-free DNA in ovarian cancer patients
Ana Barbosa et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2018)
Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
Katharina Prieske et al.
ONCOTARGET (2017)
RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA
Lydia Giannopoulou et al.
ONCOTARGET (2017)
Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
Maria Chimonidou et al.
ONCOTARGET (2017)
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer
Martin Widschwendter et al.
GENOME MEDICINE (2017)
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer
Sanjeeve Balasubramaniam et al.
CLINICAL CANCER RESEARCH (2017)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
Methylated circulating tumor DNA in blood: power in cancer prognosis and response
Kristina Warton et al.
ENDOCRINE-RELATED CANCER (2016)
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg et al.
NATURE REVIEWS GENETICS (2016)
Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer
Antje M. Richter et al.
CANCERS (2016)
DNA methylation changes in epithelial ovarian cancer histotypes
Madalene A. Earp et al.
GENOMICS (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
I. Balgkouranidou et al.
BRITISH JOURNAL OF CANCER (2014)
RASSF tumor suppressor gene family: Biological functions and regulation
Natalia Volodko et al.
FEBS LETTERS (2014)
DNA methylation markers for early detection of women's cancer: promise and challenges
Timo Wittenberger et al.
EPIGENOMICS (2014)
CST6 promoter methylation in circulating cell-free DNA of breast cancer patients
Maria Chimonidou et al.
CLINICAL BIOCHEMISTRY (2013)
SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA Isolated from Plasma of Patients with Breast Cancer
Maria Chimonidou et al.
CLINICAL CHEMISTRY (2013)
Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression
Yan-Qiu Wang et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2013)
Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer
Celine Montavon et al.
GYNECOLOGIC ONCOLOGY (2012)
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells
Maria Chimonidou et al.
CLINICAL CHEMISTRY (2011)
Inactivation of O6-methyguanine-DNA methyltransferase by promoter hypermethylation: Association of epithelial ovarian carcinogenesis in specific histological types
Hyun-Jin Roh et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An epigenetic marker panel for screening and prognostic prediction of ovarian cancer
Her-Young Su et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
